BCL2 and neoplasm: Upregulation of TOMM20 induced resistance to the BCL‐2 inhibitor venetoclax, the mitochondrial complex IV inhibitor ATO, but increases sensitivity to the complex I inhibitor methylglyoxal and increases CD8+ T‐cell tumor recruitment in the context of immune checkpoint blockade PD1